Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Sean Penn lights up, Kylie Jenner gets A-list approval and 7 other moments you didn’t see at the Golden Globes - 2Avoid Slam: Exploring the Pickup Truck Transformation
- 3How did life begin on Earth? New experiments support 'RNA world' hypothesis
- 4Jupiter and the moon take a sunset stroll on March 26. Here's how to see it
- 5In a scientific first, biologists recorded a wild wolf potentially using tools
- Arctic is again the hottest it's been in 125 years, with record-low sea ice, NOAA report says
- Grass Care Administrations for a Wonderful, Sound Yard
- National health ranking puts Georgia near bottom of list. Here's why
- Greece eyes migrant repatriation centres outside the EU
- UN experts urge investigation into Israel’s killing of Lebanese journalists
- Apartment Turned Into Nightmare 'Ice Castle' After Tenant Shut Off Heat Causing Pipes to Burst: VIDEO
- Doctor's orders: Eat ice cream, and other tips for a long and healthy life
- New movies to watch this weekend: See 'The Drama' in theaters, rent 'Wuthering Heights,' stream 'Pizza Movie' on Hulu
- Dozens injured in Russia after train crashes, overturns
